Exact Mass: 537.488259
Exact Mass Matches: 537.488259
Found 236 metabolites which its exact mass value is equals to given mass value 537.488259,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cer(d18:1/16:0)
Ceramides, also known as N-acylsphingosines, consist of a sphingoid base linked to a fatty acid chain via the amine group. Ceramides are one of the hydrolysis byproducts of sphingomyelin via the enzyme sphingomyelinase (sphingomyelin phosphorylcholine phosphohydrolase, E.C.3.1.4.12) which has been identified in the subcellular fractions of human epidermis and many other tissues (PMID: 25935). They can also be synthesized from serine and palmitate in a de novo pathway and are regarded as important cellular signals for inducing apoptosis (PMID: 14998372). Ceramides are key to the biosynthesis of glycosphingolipids and gangliosides. Cer(d18:1/16:0), in particular, consists of a monounsaturated 18-carbon dihydroxylated sphingoid base linked to one chain of palmitic acid. Ceramides (N-acylsphingosine) are one of the hydrolysis byproducts of sphingomyelin by the enzyme sphingomyelinase (sphingomyelin phosphorylcholine phosphohydrolase E.C.3.1.4.12) which has been identified in the subcellular fractions of human epidermis (PMID 25935) and many other tissues. They can also be synthesized from serine and palmitate in a de novo pathway and are regarded as important cellular signals for inducing apoptosis (PMID 14998372). Is key in the biosynthesis of glycosphingolipids and gangliosides. [HMDB] C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding[1].
(17Z)-Hexacos-17-enoylcarnitine
(17Z)-Hexacos-17-enoylcarnitine is an acylcarnitine. More specifically, it is an (17Z)-hexacos-17-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (17Z)-Hexacos-17-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (17Z)-Hexacos-17-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,2S,3R)-2-N-eicosanoyl-4-tetradecasphingenine|(4E,6E,2S,3R)-2-N-Eicosanoyl-4,6-tetradecasphingadienine
(3S,4S,5R)-3-octadecanoylamino-4-hydroxy-5-dodecane-2,3,4,5-tetrahydrofuran
(2S,2R,3R,4E,8E)-N-2-hydroxytetradecanoyl-2-amino-9-methyl-4,8-octadecadiene-1,3-diol
Cer[NS] d34:1
Found in mouse small intestine; TwoDicalId=23; MgfFile=160907_Small_Intestine_AA_Neg_17; MgfId=1444
c16 ceramide
C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding[1].
C16-Ceramide
N-Palmitoylsphingosine is a substrate for N-acylethanolamine-hydrolyzing acid amidase. [HMDB] C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding[1].
N-heptadecanoyl-14-methylhexadecasphingosine
A ceramide obtained by formal condensation of the carboxy group of heptadecanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.
(Z)-N-(1,3-dihydroxyhexadecan-2-yl)octadec-9-enamide
N-[(E)-1,3-dihydroxyhentriacont-4-en-2-yl]propanamide
N-[(E)-1,3-dihydroxyheptacos-4-en-2-yl]heptanamide
N-[(E)-1,3-dihydroxydotriacont-4-en-2-yl]acetamide
N-[(E)-1,3-dihydroxytridec-4-en-2-yl]henicosanamide
(Z)-N-(1,3-dihydroxyhenicosan-2-yl)tridec-9-enamide
(Z)-N-(1,3-dihydroxyoctadecan-2-yl)hexadec-9-enamide
(Z)-N-(1,3-dihydroxydecan-2-yl)tetracos-13-enamide
(Z)-N-(1,3-dihydroxyheptadecan-2-yl)heptadec-9-enamide
(Z)-N-(1,3-dihydroxytridecan-2-yl)henicos-11-enamide
(E)-N-[(2S,3R)-1,3-dihydroxyhexadecan-2-yl]octadec-9-enamide
(E)-N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]hexadec-9-enamide
N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]octadecanamide
(Z)-N-[(E)-1,3,4-trihydroxyhenicos-8-en-2-yl]dodec-5-enamide
N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]icosanamide
(Z)-N-[(E)-1,3,4-trihydroxynonadec-8-en-2-yl]tetradec-9-enamide
N-[(8E,12E)-1,3,4-trihydroxyheptadeca-8,12-dien-2-yl]hexadecanamide
(Z)-N-(1,3-dihydroxyicosan-2-yl)tetradec-9-enamide
N-[(E)-1,3-dihydroxynonadec-4-en-2-yl]pentadecanamide
(Z)-N-(1,3-dihydroxytetradecan-2-yl)icos-11-enamide
(Z)-N-(1,3-dihydroxynonadecan-2-yl)pentadec-9-enamide
N-[(E)-1,3-dihydroxyhenicos-4-en-2-yl]tridecanamide
N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]nonadecanamide
N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]nonadecanamide
(Z)-N-[(E)-1,3,4-trihydroxyoctadec-8-en-2-yl]pentadec-9-enamide
(Z)-N-(1,3-dihydroxypentadecan-2-yl)nonadec-9-enamide
N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]heptadecanamide
(10Z,12Z)-N-(1,3,4-trihydroxypentadecan-2-yl)octadeca-10,12-dienamide
(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]octadec-11-enamide
N-[(8E,12E)-1,3,4-trihydroxyoctadeca-8,12-dien-2-yl]pentadecanamide
N-[(8E,12E)-1,3,4-trihydroxyicosa-8,12-dien-2-yl]tridecanamide
(Z)-N-[(E)-1,3,4-trihydroxyicos-8-en-2-yl]tridec-8-enamide
N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]heptadecanamide
N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]octadecanamide
(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]nonadec-9-enamide
N-[(8E,12E)-1,3,4-trihydroxyhenicosa-8,12-dien-2-yl]dodecanamide
(4Z,7Z)-N-(1,3,4-trihydroxyheptadecan-2-yl)hexadeca-4,7-dienamide
N-[(8E,12E)-1,3,4-trihydroxynonadeca-8,12-dien-2-yl]tetradecanamide
N-[(E)-1,3-dihydroxyicos-4-en-2-yl]tetradecanamide
(Z)-N-[(E)-1,3,4-trihydroxyheptadec-8-en-2-yl]hexadec-7-enamide
(Z)-N-(1,3-dihydroxyhenicosan-2-yl)tridec-8-enamide
(Z)-N-(1,3-dihydroxyoctadecan-2-yl)hexadec-7-enamide
(Z)-N-(1,3-dihydroxyhexadecan-2-yl)octadec-11-enamide
N-[(E,2S,3R)-1,3-dihydroxypentadec-8-en-2-yl]nonadecanamide
N-[(E,2S,3R)-1,3-dihydroxyhexadec-8-en-2-yl]octadecanamide
(E)-N-[(2S,3R)-1,3-dihydroxytetradecan-2-yl]icos-11-enamide
N-[(E,2S,3R)-1,3-dihydroxydocos-8-en-2-yl]dodecanamide
N-[(E,2S,3R)-1,3-dihydroxyicos-8-en-2-yl]tetradecanamide
N-[(E,2S,3R)-1,3-dihydroxynonadec-8-en-2-yl]pentadecanamide
(E)-N-[(2S,3R)-1,3-dihydroxyheptadecan-2-yl]heptadec-9-enamide
N-[(E,2S,3R)-1,3-dihydroxyheptadec-8-en-2-yl]heptadecanamide
N-[(E,2S,3R)-1,3-dihydroxytetradec-8-en-2-yl]icosanamide
N-[(E,2S,3R)-1,3-dihydroxyhenicos-8-en-2-yl]tridecanamide
9-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 9-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
5-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 5-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
11-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 11-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
10-PAHSA
A FAHFA obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 10-hydroxystearic acid.
N-Hexadecanoylsphingosine
A N-acylsphingosine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).
10-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 10-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 12-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
13-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 13-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
7-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 7-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
8-PAHSA(1-)
A long-chain fatty acid anion that is the conjugate base of 8-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.
n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanimidic acid
(2s,2'r,3r,4 e,8 e)-n-2'-hydroxytetradecanoyl-2-amino-9-methyl-4,8-octadecadiene-1,3-diol
{"Ingredient_id": "HBIN006608","Ingredient_name": "(2s,2'r,3r,4 e,8 e)-n-2'-hydroxytetradecanoyl-2-amino-9-methyl-4,8-octadecadiene-1,3-diol","Alias": "NA","Ingredient_formula": "C33H63NO4","Ingredient_Smile": "CCCCCCCCCCCCC(C(=O)NC(CO)C(C=CCCC=C(C)CCCCCCCCC)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10743","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
